Abstract: Methods and systems may perform cell-free identification and/or monitoring of pregnancy-related states. A method for identifying or monitoring a presence or susceptibility of a pregnancy-related state of a subject may comprise assaying a cell-free biological sample derived from the subject to detect a set of biomarkers, and analyzing the set of biomarkers with a trained algorithm to determine the presence or susceptibility of the pregnancy-related state.
Abstract: Methods and systems may perform cell-free identification and/or monitoring of pregnancy-related states. A method for identifying or monitoring a presence or susceptibility of a pregnancy-related state of a subject may comprise assaying a cell-free biological sample derived from the subject to detect a set of biomarkers, and analyzing the set of biomarkers with a trained algorithm to determine the presence or susceptibility of the pregnancy-related state.
Abstract: Disclosed is a technology for assaying individual cells, in which the identity of each individual cell in an ordered array is determined from coordinates assigned to it, and can be readout at high throughput with microscope. The method is able to test responses of millions of identical cells in multiple chemical and physical processes with superior statistics power to facilitate deep data mining.
Type:
Grant
Filed:
March 6, 2020
Date of Patent:
December 19, 2023
Assignee:
Northeastern University
Inventors:
Ming Su, Qingxuan Li, Liyuan Ma, Sidi A. Bencherif, Thibault Colombani
Abstract: The disclosure relates to compositions comprising and methods for chemical modification of single guide RNA (sgRNA), tracrRNA and/or crRNA used individually or in combination with one another or Cas system components. Compositions comprising modified ribonucleic acids have been designed with chemical modification for even higher efficiency as unmodified native strand of sgRNA. Administration of modified ribonucleic acids will allow decreased immune response when administered to a subject, increased stability, increased editing efficiency and facilitated in vivo delivery of sgRNA via various delivery platforms. The disclosure also relates to methods of decreasing off-target effect of CRISPR and a CRISPR complex.
Type:
Grant
Filed:
February 3, 2017
Date of Patent:
December 19, 2023
Assignee:
Massachusetts Institute of Technology
Inventors:
Hao Yin, Daniel G. Anderson, Robert S. Langer
Abstract: Provided herein are methods and compositions for performing highly sensitive in vitro assays to define substrate preferences and off-target sites of nucleic-acid binding, modifying, and cleaving agents.
Type:
Grant
Filed:
April 17, 2020
Date of Patent:
December 19, 2023
Assignee:
The General Hospital Corporation
Inventors:
J. Keith Joung, Vikram Pattanayak, Karl Petri
Abstract: The present invention relates to methods of introducing multiple expression constructs into a eukaryotic cell, methods of constructing a eukaryotic cell having multiple target loci for expressing multiple heterologous proteins of interest, eukaryotic cells for expressing multiple heterologous proteins of interest, and methods of production of multiple heterologous proteins of interest.
Type:
Grant
Filed:
July 9, 2019
Date of Patent:
December 12, 2023
Assignee:
Novozymes A/S
Inventors:
Qiming Jin, Jeffrey Shasky, Donna Moyer, Abigail Jang, Gloria Muzzi-Erichsen, Cara Kleindienst
Abstract: Disclosed herein are compositions that comprise engineered polynucleotides, pharmaceutical compositions comprising the same, methods of making the same, and methods of treatment comprising the compositions that comprise the engineered polynucleotides.
Type:
Grant
Filed:
December 1, 2020
Date of Patent:
November 28, 2023
Assignee:
Shape Therapeutics Inc.
Inventors:
David Huss, Prashant Mali, Anupama Lakshmanan, Christopher Nye, Yiannis Savva, Liana Stein, Richard Sullivan, Rafael Ponce, Susan Byrne
Abstract: The present disclosure provides donor polynucleotides, genome editing systems, methods, pharmaceutical compositions, and kits which correct or induce a mutation that causes Glycogen Storage Disease 1a in a genomic DNA molecule in a cell. In some embodiments the present disclosure provides donor polynucleotides comprising two strands capable of correcting a mutation that causes Glycogen Storage Disease 1a.
Type:
Grant
Filed:
June 28, 2019
Date of Patent:
November 28, 2023
Assignee:
CRISPR THERAPEUTICS AG
Inventors:
Troy Dean Carlo, Roman Lvovitch Bogorad
Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.
Type:
Grant
Filed:
May 24, 2022
Date of Patent:
November 28, 2023
Assignees:
LONZA WALKERSVILLE, INC., LONZA COLOGNE GMBH, OCTANE BIOTECH INC.
Inventors:
Yaling Shi, Erika McAfee, Samatha Bandapalle, Ann Siehoff, Timo Gleissner, Joseph O'Connor, Eytan Abraham, Kelly Purpura, Nuala Trainor, Timothy Smith
Abstract: The present disclosure relates to compositions of matter and assay methods used to detect one or more target nucleic acids of interest in a sample. The compositions and methods allow one to control reaction kinetics of the cascade assay by two orders of magnitude via molecular design of one of the reaction components; further, varying molecular design also allows for quantification of target nucleic acids of interest over a large range of concentrations or discriminating between extremely low copy numbers of target nucleic acids of interest.
Type:
Grant
Filed:
December 6, 2022
Date of Patent:
November 21, 2023
Assignee:
LabSimply, Inc.
Inventors:
Anurup Ganguli, Ariana Mostafa, Jacob Berger, Ashish Pandey
Abstract: The problem to be solved is to provide a novel expression vector capable of effectively expressing a target protein in mitochondria and suppressing undesirable expression of the target protein in cell organelles other than mitochondria. The present invention provides a recombinant expression vector for expressing a target protein in mitochondria of animal cells, and a lipid membrane structure having the vector encapsulated therein, wherein the recombinant expression vector has a promoter sequence exhibiting a transcription activity in the nuclei of animal cells, and has, under the control of the promoter sequence, a coding region which codes a target protein and includes one or more TGAs as codons corresponding to tryptophan. The recombinant expression vector according to the present invention can more efficiently and selectively express a target protein in mitochondria, and can be used as a more safe and effective drug for treating mitochondrial diseases.
Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
Type:
Grant
Filed:
February 14, 2019
Date of Patent:
November 14, 2023
Assignee:
Bristol-Myers Squibb Company
Inventors:
Sharon Cload, Linda Engle, Dasa Lipovsek, Malavi Madireddi, Ginger Chao Rakestraw, Joanna Swain, Wenjun Zhao, Hui Wei, Aaron P. Yamniuk, Vidhyashankar Ramamurthy, Alexander T. Kozhich, Martin J. Corbett, Stanley Richard Krystek, Jr.
Abstract: The present invention relates to enhanced Sleeping Beauty-type transposons and methods of transposition. In particular the invention relates to a polynucleotide comprising a cargo nucleic acid flanked by a left and a right inverted repeat/direct repeat (IR/DR), wherein IR/DRs, having specific sequences, are recognized by a Sleeping Beauty transposase protein and the polynucleotide is capable of integrating into the DNA of a cell.
Type:
Grant
Filed:
March 15, 2017
Date of Patent:
November 14, 2023
Assignee:
Max-Delbrück-Centrum für Molekulage Medizin in der Helmholtz-Gemeinschaft.
Inventors:
Zsuzsanna Izsvák, Zoltán Ivics, Christopher Kaufman, Suneel Narayanavari
Abstract: Compositions, methods and kits are provided. The compositions, methods and kits are for assembly of series of DNA segments in yeast using homologous recombination. The assembled DNA segments are maintained episomally. Yeast made using the methods are included, as are methods of using the yeast to express proteins, and for screening test agents that can affect yeast that are modified to include the assembled DNA segments.
Type:
Grant
Filed:
July 7, 2017
Date of Patent:
November 14, 2023
Assignee:
New York University
Inventors:
Jef D. Boeke, Leslie A. Mitchell, Neta Agmon
Abstract: A method for detecting oncogenic growth and viability, and/or degree of cellular transformation and/or identifying an agent that inhibits cellular transformation is disclosed. The method including: providing a cellular sample, such as a sample of cells obtained from a subject or a cell line; culturing the cellular sample in low attachment conditions; and detecting growth and7or cell viability of the sample, wherein increased growth relative and/or viability relative to a control or control level indicative of basal growth and/or viability indicates cellular transformation. In some embodiments, the method includes introducing a n expression vector into cells of the cellular sample, wherein the expression vector comprises a gene product expression sequence being tested for transformation ability. In some embodiments the cellular sample is contacted with a test agent and growth and/or cell viability of the sample is determined to determine if the agent inhibits transformation.
Type:
Grant
Filed:
March 24, 2016
Date of Patent:
November 7, 2023
Assignees:
THE BROAD INSTITUTE, INC., DANA FARBER CANCER INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE, MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Inventors:
Asaf Rotem, Kevin Struhl, Paul Blainey, Liyi Xu
Abstract: The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered CRISPR systems, components, and methods for targeted modification of nucleic acids. Each system includes one or more protein components and one or more nucleic acid components that together target nucleic acids.
Type:
Grant
Filed:
August 17, 2022
Date of Patent:
October 24, 2023
Assignee:
ARBOR BIOTECHNOLOGIES, INC.
Inventors:
David A. Scott, David R. Cheng, Winston X. Yan, Tia M. DiTommaso
Abstract: Embodiments disclosed herein provide artificial expression systems comprising multivalent transcription factor complexes for cooperative transcription factor assembly and modulating gene expression. More specifically, engineered synthetic transcription factors are recruited and structurally organized on synthetic gene circuits using molecular clamps, where the strength of intra-complex interactions can be modulated for fine tuning of gene expression as desired.
Type:
Grant
Filed:
June 28, 2019
Date of Patent:
October 10, 2023
Assignee:
Trustees of Boston University
Inventors:
Ahmad S. Khalil, Caleb J. Bashor, Nikit Patel, James J. Collins
Abstract: The invention relates to recombinant host cells that expresses one or more genes encoding a cytochrome P450 enzyme capable of N-demethylating and/O-demethylating reticuline and/or derivatives thereof, and also methods of producing a N-demethylated and/or O-demethylated reticuline and/or derivatives thereof, comprising cultivating the recombinant host of the invention in a culture medium under conditions in which the one or more genes encoding the cytochrome P450 enzymes is/are expressed. The reticuline and derivatives thereof are useful for providing access to naturally unavailable and chemically difficult-to-produce starting materials for opioids.
Type:
Grant
Filed:
June 18, 2018
Date of Patent:
October 10, 2023
Assignee:
RIVER STONE BIOTECH, LLC
Inventors:
Markus Schwab, Sumire Honda Malca, Philipp Friedrich Berninger, Jon Richard Heal, Joseph Michael Sheridan, Laura Tatjer Recorda, Rubini Maya Kannangara, Esben Halkjaer Hansen, Angela Manuela Ribeiro de Carvalho
Abstract: The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a novel DNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA. Methods for making and using and uses of such systems, methods, and compositions and products from such methods and uses are also disclosed and claimed.
Type:
Grant
Filed:
April 30, 2019
Date of Patent:
October 10, 2023
Assignees:
THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Inventors:
Feng Zhang, Bernd Zetsche, Jonathan S. Gootenberg, Omar O. Abudayyeh, Ian Slaymaker
Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.
Type:
Grant
Filed:
May 24, 2022
Date of Patent:
October 10, 2023
Assignees:
LONZA WALKERSVILLE, INC., LONZA COLOGNE GMBH, OCTANE BIOTECH INC.
Inventors:
Yaling Shi, Erika McAfee, Samatha Bandapalle, Ann Siehoff, Timo Gleissner, Joseph O'Connor, Eytan Abraham, Kelly Purpura, Nuala Trainor, Timothy Smith